跳至主要内容
临床试验/NCT04486222
NCT04486222
终止
不适用

Therapeutic Effect of Accelerated Bilateral Repeated Transcranial Magnetic Stimulation on Geriatric Depression: a Prospective Double-blind, Randomized Controlled Trial

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 2 人2020年11月23日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Transcranial Magnetic Stimulation
发起方
National Taiwan University Hospital
入组人数
2
试验地点
1
主要终点
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
状态
终止
最后更新
3年前

概览

简要总结

This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.

详细描述

Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety. Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS. In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.

注册库
clinicaltrials.gov
开始日期
2020年11月23日
结束日期
2022年12月21日
最后更新
3年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • age between 60-85 years
  • literate and received basic education for at least 2 years
  • diagnosis of major depressive disorder, without psychotic features, according to DSM-5
  • have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
  • failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
  • psychoactive agents were in stable doses before randomization

排除标准

  • active suicide plans or attempts; or suicide attempts in the last 12 months
  • diagnosis of schizophrenia or bipolar disorder according to DSM-5
  • have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
  • have delirium, major neurocognitive disorder or MMSE \< 24
  • current use of bupropion \>300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
  • history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
  • with a cardiac pacemaker or defibrillator
  • received rTMS treatment before

结局指标

主要结局

Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)

时间窗: day 1, day 5, day 12, day 19

HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17.

次要结局

  • Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)(day 1, day 5, day 12, day 19)
  • Degree of Change in Mini-Mental State Examination (MMSE)(day 1, day 5, day 12, day 19)
  • Degree of Change in Stroop Test(day 1, day 5, day 12, day 19)
  • Degree of Change in Trail Making Test(day 1, day 5, day 12, day 19)
  • Degree of Change in Verbal Fluency Test(day 1, day 5, day 12, day 19)
  • Degree of Change in Physiological Parameters(day 1, day 5, day 12, day 19)

研究点 (1)

Loading locations...

相似试验